OpenURL Connection Search

Select item for more details and to access through your institution.

Overall safety profile of boceprevir plus peginterferon alfa-2b and ribavirin in patients with chronic hepatitis C genotype 1: a combined analysis of 3 phase 2/3 clinical trials.
Published in:
Liver International, 2014, v. 34, n. 5, p. 707, doi. 10.1111/liv.12300
By:
- Manns, Michael P.;
- McCone, Jonathan;
- Davis, Mitchell N.;
- Rossaro, Lorenzo;
- Schiff, Eugene;
- Shiffman, Mitchel L.;
- Bacon, Bruce;
- Bourliere, Marc;
- Sulkowski, Mark S.;
- Bruno, Savino;
- Balart, Luis;
- Bronowicki, Jean‐Pierre;
- Kwo, Paul;
- Poordad, Fred;
- Felizarta, Franco;
- Reddy, K. Rajender;
- Helmond, Frans A.;
- Sings, Heather L.;
- Pedicone, Lisa D.;
- Burroughs, Margaret
Publication type:
Article
Hepatitis C Point-of-Care Screening in Retail Pharmacies in the United States.
Published in:
Gastroenterology & Hepatology, 2017, v. 13, n. 2, p. 98
By:
- Kugelmas, Marcelo;
- Pedicone, Lisa D.;
- Lio, Idania;
- Simon, Susan;
- Pietrandoni, Glen
Publication type:
Article
Infections During Peginterferon/Ribavirin Therapy Are Associated With the Magnitude of Decline in Absolute Lymphocyte Count: Results of the IDEAL Study.
Published in:
Clinical Infectious Diseases, 2014, v. 58, n. 7, p. 960, doi. 10.1093/cid/ciu009
By:
- Melia, Michael T.;
- Bräu, Norbert;
- Poordad, Fred;
- Lawitz, Eric J.;
- Shiffman, Mitchell L.;
- McHutchison, John G.;
- Muir, Andrew J.;
- Galler, Greg W.;
- Nyberg, Lisa M.;
- Lee, William M.;
- Schiff, Eugene;
- Long, Jianmin;
- Noviello, Stephanie;
- Brass, Clifford A.;
- Pedicone, Lisa D.;
- Sulkowski, Mark S.
Publication type:
Article

Found: 3

Overall safety profile of boceprevir plus peginterferon alfa-2b and ribavirin in patients with chronic hepatitis C genotype 1: a combined analysis of 3 phase 2/3 clinical trials.

Hepatitis C Point-of-Care Screening in Retail Pharmacies in the United States.

Infections During Peginterferon/Ribavirin Therapy Are Associated With the Magnitude of Decline in Absolute Lymphocyte Count: Results of the IDEAL Study.